News from i-mab biopharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 25, 2019, 10:01 ET I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States

I-Mab Biopharma ("I-Mab"), a clinical stage biotech company exclusively focusing on discovery and development of innovative biologics in...


Apr 29, 2019, 17:01 ET I-Mab Biopharma and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Study of TJ202/MOR202 in Multiple Myeloma

I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in...


Apr 16, 2019, 08:34 ET I-Mab Biopharma and WuXi Biologics Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs

I-Mab Biopharma ("I-Mab"), a biotech company focusing exclusively on innovative biologics in immuno-oncology and auto-immune diseases, and WuXi...


Apr 10, 2019, 22:34 ET I-Mab Biopharma Signs Agreement for Clinical Research of TJD5 in Combination Therapy

I-Mab Biopharma ("I-Mab"), a clinical stage biopharmaceutical company exclusively focused on the development of potential first-in-class and...


Apr 07, 2019, 21:01 ET I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical Announce Strategic Collaboration Agreement with Biodextris and a Boston-Based, Leading Academic Medical Center

I-Mab Biopharma (I-Mab), a clinical stage biotech company based in Shanghai with an exclusive focus on the development of potential first-in-class...


Mar 19, 2019, 17:05 ET I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in...


Mar 19, 2019, 06:00 ET I-Mab Biopharma Announces Dosing of First Subject in Phase 1 Clinical Trial of Anti-GM-CSF Monoclonal Antibody TJM2 in the United States

I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in...


Mar 05, 2019, 02:30 ET I-Mab Biopharma Announces the Achievement of First Patient Dosing in Phase 1b/2a China Trial of TJ107 for Cancer and Chemotherapy-induced Lymphopenia

I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in...


Feb 01, 2019, 04:46 ET I-Mab Biopharma and Bio-Cancer Treatment International Announce Intention for Collaboration on Arginine Depletion Therapy and Biomarker Study, with Plans for I-Mab to Establish a Translational Medicine Lab in Hong Kong

I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in...


Jan 28, 2019, 08:58 ET I-Mab Receives IND Approval from the US FDA to Initiate Clinical Trials for Its Proprietary TJC4, a Potential Global Best-in-Class Anti-CD47 Monoclonal Antibody

I-Mab Biopharma ("I-Mab"), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in...


Jan 22, 2019, 09:04 ET I-Mab Biopharma Receives U.S. FDA IND Clearance for Proprietary CD73 Antibody TJD5

I-Mab Biopharma ("I-Mab"), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in...


Dec 23, 2018, 22:45 ET I-Mab Receives U.S. FDA IND Approval for Proprietary Anti-GM-CSF Monoclonal Antibody TJM2

I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in...


Dec 17, 2018, 06:10 ET I-Mab and CSPC Pharma Announce Strategic Partnership for Long-acting GLP-1 Fc Program

I-Mab Biopharma ("I-Mab"), a China-based clinical stage biopharmaceutical company focused on the development of innovative biologics in...


Nov 29, 2018, 02:40 ET TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...


Nov 15, 2018, 16:01 ET MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab Biopharma ("I-Mab"), a biotech company focusing exclusively on...


Nov 02, 2018, 09:06 ET I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy

I-MAB Biopharma Co., Ltd. ("I-Mab"), a Shanghai-based biotech company exclusively focused on innovative biologics in immuno-oncology and autoimmune...


Oct 12, 2018, 02:01 ET First Patient Dosing achieved in Mainland China in a Phase II Multi-regional clinical trial (MRCT)

I-Mab Biopharma ("I-Mab"), a company focusing on innovative biologics in immuno-oncology and immuno-inflammation, today announced that the first...


Sep 26, 2018, 09:23 ET I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Sep 19, 2018, 03:33 ET I-Mab Wins Frost & Sullivan "2018 Best R&D Innovator Award (Biopharma Category)"

I-Mab Biopharma ("I-Mab") announced today that it has been recognized by Forest & Sullivan, the global leading growth consulting company as well as...


Aug 09, 2018, 04:16 ET I-Mab's Announces China Clinical Trial Approval of Long-acting hGLP-1 to Treat Type 2 Diabetes

In July, 2018, I-Mab Biopharma (I-Mab) announced that it received clinical trial approval from China National Drug Administration (CNDA) for TJ103...


Aug 07, 2018, 21:01 ET I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202

On August 8, 2018 Beijing time I-Mab Biopharma ("I-Mab"), a Shanghai-based biotech company focused on innovative biologics in oncology and autoimmune ...


Jul 31, 2018, 20:44 ET I-Mab Biopharma Announces New CFO

On August 1, 2018 Beijing time, I-Mab Biopharma ("I-Mab"), a Shanghai-based biotech company focused on innovative biologics in oncology and...


Jul 26, 2018, 09:30 ET I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies

I-Mab Biopharma ("I-Mab"), a company focusing on innovative biologics in immuno-oncology and immuno-inflammation, and ABL Bio Corporation ("ABL...


Jun 29, 2018, 05:42 ET I-Mab Successfully Raised USD 220 Million in Series C Funding

I-Mab Biopharma, a company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, announced the completion ...


Dec 25, 2017, 05:50 ET I-Mab Biopharma Signs Licensing Agreement for HyLeukin With Genexine

- Genexine to receive an upfront payment and entitled to tiered, single-digit royalties on net sales of HyLeukin plus milestone payments from I-Mab...